Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP

PURPOSE: Alectinib is an anaplastic lymphoma kinase (ALK) –specific kinase inhibitor that seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overall response rate. To assess progression-free survival...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Tamura, Tomohide, Kiura, Katsuyuki, Seto, Takashi, Nakagawa, Kazuhiko, Maemondo, Makoto, Inoue, Akira, Hida, Toyoaki, Yoshioka, Hiroshige, Harada, Masao, Ohe, Yuichiro, Nogami, Naoyuki, Murakami, Haruyasu, Kuriki, Hiroshi, Shimada, Tadashi, Tanaka, Tomohiro, Takeuchi, Kengo, Nishio, Makoto
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2017
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455704/
https://ncbi.nlm.nih.gov/pubmed/28296581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.5749
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars